WuXi STA Debuts Its First High Potency Sterile Injectable Manufacturing Line at Wuxi City Site
WuXi STA, a renowned Contract Research, Development, and Manufacturing Organization (CRDMO), made a groundbreaking announcement recently. The company has initiated a high potency, fully automated sterile injectable manufacturing line at its Wuxi City site, upping its manufacturing capabilities and capacity in response to the high potency pharmaceuticals market.
One of the major highlights of this line is its dedication to maintaining a sterile environment. The fully enclosed isolation systems and automated filling machines work together to reduce human interaction, decreasing the risk of cross-contamination and ensuring high product quality. In terms of safety, an independent air conditioning system and a bag-in bag-out (BIBO) exhaust air purification system have been included, offering reassurance to operators.
But WuXi STA is not stopping there. By 2024, it aims to launch two more injectable manufacturing lines at the Wuxi City site, extending its capacity and capabilities even further. Dr. Minzhang Chen, the Co-CEO of WuXi AppTec and CEO of WuXi STA, reflects on this development, reasserting WuXi STA’s commitment to expedite pharmaceutical development and advance patient care worldwide.
Author
